Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.

Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.

Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.

Scientists at Max Planck Florida have developed a tool that allows for precise genome editing of neurons.

In our EuroBiotech roundup this week, Lytix prepares for IPO, Roche advances Alzheimer’s asset and Antabio raises cash for antibiotic trial. 

In this week's EuroBiotech Report, Lilly and CureVac pen $1.8 billion mRNA pact, AstraZeneca reveals Brexit pain, uniQure switches drugs and more.

The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.

Microbiome startup AOBiome Therapeutics has seen positive data from its phase 2b trial in acne.

People are turning down jobs at AstraZeneca because of uncertainty about their right to stay in the United Kingdom after Brexit.

The mid-development tweaks have the blessing of regulators, enabling uniQure to start a pivotal trial next year with its fast-track statuses intact.